Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Open Access
- 1 July 2007
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (6), 737-748
- https://doi.org/10.1038/sj.bjp.0707253
Abstract
New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful. The relative toxicity of TCAs continues to be more precisely defined, as do TCA interactions with selective serotonin reuptake inhibitors (SSRIs). TCA interactions with monoamine oxidase inhibitors (MAOIs) have been, historically, an uncertain and difficult question, but are now well understood, although this is not reflected in the literature. The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs. Clomipramine is the only available antidepressant drug that has good evidence of clinically relevant serotonin and noradrenaline reuptake inhibition (SNRI). These data assist drug selection for monotherapy and combination therapy and predict reliably how and why pharmacodynamic and pharmacokinetic interactions occur. In comparison, two newer drugs proposed to have SNRI properties, duloxetine and venlafaxine, may have insufficient NRI potency to be effective SNRIs. Combinations such as sertraline and nortriptyline may therefore offer advantages over drugs like venlafaxine that have fixed ratios of SRI/NRI effects that are not ideal. However, no TCA/SSRI combination is sufficiently safe to be universally applicable without expert knowledge. Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings.Keywords
This publication has 124 references indexed in Scilit:
- Regulation of Clinical Research Sponsored by Pharmaceutical Companies: A ProposalPLoS Medicine, 2006
- Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteersInternational Journal of Neuropsychopharmacology, 2006
- Pharmacological treatment for unipolar psychotic depressionThe British Journal of Psychiatry, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Drug interactions and fluoxetine: a commentary from a clinician’s perspectiveExpert Opinion on Drug Safety, 2005
- Antidepressant drugs for narcolepsyPublished by Wiley ,2005
- Tricyclic Antidepressant PoisoningToxicological Reviews, 2005
- Can the Fatal Toxicity of Antidepressant Drugs be Predicted with Pharmacological and Toxicological Data?Drug Safety, 1998
- Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsPharmacological Research, 1995
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sciences, 1993